Skip to content
lifestyle.toptraveltrends.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Elicio Therapeutics Inc.
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
August 10, 2026
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
June 1, 2026
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 11, 2026
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
April 30, 2026
Elicio Therapeutics Reports Inducement Grants
April 16, 2026
Elicio Therapeutics Reports Inducement Grants
March 17, 2026
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
March 12, 2026
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 25, 2026
Elicio Therapeutics Reports Inducement Grants
February 18, 2026